Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma.

ABSTRACT:

Background and rationale

Immune checkpoint inhibitor (ICI) therapy is an expanding therapeutic option for hepatocellular carcinoma (HCC). Antibiotics (ATB) taken prior to or early during ICI therapy can impact immunotherapy efficacy across indications; however, the effect of ATB is undefined in HCC.

Methods

In a large international cohort of 450 ICI recipients from Europe, North America, and Asia, we categorized patients according to timing of ATB focusing on exposure within -30 to +30 days from ICI (early immunotherapy period [EIOP]). EIOP was evaluated in association with overall survival (OS), progression-free survival (PFS), and best radiologic response using RECIST 1.1 criteria.

Results

Our study comprised mostly cirrhotic (329, 73.3%) males (355, 79.1%) with a C

SUBMITTER: Fessas P 

PROVIDER: S-EPMC8647090 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature